Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

被引:68
作者
Chen, XN
Scala, G
Quinto, I
Liu, WM
Chun, TW
Justement, JS
Cohen, OJ
vanCott, TC
Iwanicki, M
Lewis, MG
Greenhouse, J
Barry, T
Venzon, D
Fauci, AS
机构
[1] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[2] Univ Catanzaro, Sch Med, Dept Clin & Expt Med, Catanzaro, Italy
[3] Univ Naples Federico II, Sch Med, Dept Biochem & Biomed Technol, Naples, Italy
[4] HM Jackson Fdn, Rockville, MD USA
[5] So Res Inst, Frederick, MD USA
[6] NCI, Hematopathol Sect, NIH, Bethesda, MD 20892 USA
[7] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1038/nm1101-1225
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antigenic polymorphism of HIV-1 is a major obstacle in developing an effective vaccine. Accordingly, we screened random peptide libraries (RPLs) displayed on phage with antibodies from HIV-infected individuals and identified an array of HIV-specific epitopes that behave as antigenic mimics of conformational epitopes of gp120 and gp41 proteins. We report that the selected epitopes are shared by a collection of HIV-1 isolates of clades A-F. The phage-borne epitopes are immunogenic in rhesus macaques, where they elicit envelope-specific antibody responses. Upon intravenous challenge with 60 MID50 of pathogenic SHIV-89.6PD, all monkeys became infected; however, in contrast to the naive and mock-immunized monkeys, four of five mimotope-immunized monkeys experienced lower levels of peak viremia, followed by viral set points of undetectable or transient levels of viremia and a mild decline of CD4(+) T cells, and were protected from progression to AIDS-like illness. These results provide a new approach to the design of broadly protective HIV-1 vaccines.
引用
收藏
页码:1225 / 1231
页数:7
相关论文
共 44 条
[1]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[2]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[3]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[4]   HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996 [J].
Beyrer, C ;
Vancott, TC ;
Peng, NK ;
Artenstein, A ;
Duriasamy, G ;
Nagaratnam, M ;
Saw, TL ;
Hegerich, PA ;
Loomis-Price, LD ;
Hallberg, PL ;
Ettore, CA ;
Nelson, KE .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (18) :1687-1691
[5]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[6]   Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques [J].
Cho, MW ;
Kim, YB ;
Lee, MK ;
Gupta, KC ;
Ross, W ;
Plishka, R ;
Buckler-White, A ;
Igarashi, T ;
Theodore, T ;
Byrum, R ;
Kemp, C ;
Montefiori, DC ;
Martin, MA .
JOURNAL OF VIROLOGY, 2001, 75 (05) :2224-2234
[7]   Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells:: Implications for the development of therapeutic strategies [J].
Chun, TW ;
Justement, JS ;
Moir, S ;
Hallahan, CW ;
Ehler, LA ;
Liu, SY ;
McLaughlin, M ;
Dybul, M ;
Mican, JM ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :253-258
[8]   Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [J].
Connor, RI ;
Korber, BTM ;
Graham, BS ;
Hahn, BH ;
Ho, DD ;
Walker, BD ;
Neumann, AU ;
Vermund, SH ;
Mestecky, J ;
Jackson, S ;
Fenamore, E ;
Cao, Y ;
Gao, F ;
Kalams, S ;
Kunstman, KJ ;
McDonald, D ;
McWilliams, N ;
Trkola, A ;
Moore, JP ;
Wolinsky, SM .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1552-1576
[9]   Selection of biologically active peptides by phage display of random peptide libraries [J].
Cortese, R ;
Monaci, P ;
Luzzago, A ;
Santini, C ;
Bartoli, F ;
Cortese, I ;
Fortugno, P ;
Galfre, G ;
Nicosia, A ;
Felici, F .
CURRENT OPINION IN BIOTECHNOLOGY, 1996, 7 (06) :616-621
[10]   A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates [J].
Cotropia, J ;
Ugen, KE ;
Kliks, S ;
Broliden, K ;
Broliden, PA ;
Hoxie, JA ;
Srikantan, V ;
Williams, WV ;
Weiner, DB .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (03) :221-232